ESI-TBVI
"Establishment, Strategy and Initial activities of the TuBerculosis Vaccine Initiative : Coordination of European efforts with global research initiatives."
| Coordinatore | "ID-LELYSTAD, INSTITUUT VOOR DIERHOUDERIJ EN DIERGEZONDHEID B.V."
Organization address
address: Edelhertweg 15 contact info |
| Nazionalità Coordinatore | Netherlands [NL] |
| Totale costo | 520˙146 € |
| EC contributo | 429˙601 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2007-B |
| Funding Scheme | CSA-SA |
| Anno di inizio | 2008 |
| Periodo (anno-mese-giorno) | 2008-05-01 - 2010-04-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
"ID-LELYSTAD, INSTITUUT VOOR DIERHOUDERIJ EN DIERGEZONDHEID B.V."
Organization address
address: Edelhertweg 15 contact info |
NL (LELYSTAD) | coordinator | 0.00 |
| 2 |
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE
Organization address
address: KEPPEL STREET contact info |
UK (LONDON) | participant | 0.00 |
| 3 |
MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.
Organization address
address: Hofgartenstrasse 8 contact info |
DE (MUENCHEN) | participant | 0.00 |
| 4 |
STATENS SERUM INSTITUT
Organization address
address: ARTILLERIVEJ 5 contact info |
DK (KOBENHAVN S) | participant | 0.00 |
| 5 |
STICHTING TUBERCULOSIS VACCINE INITIATIVE
Organization address
address: Runderweg 6 contact info |
NL (LELYSTAD) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The goal is to establish a TB Vaccine Initiative (TBVI) as a private public partnership. It will ensure an appropriate linkage between EC supported projects and global initiatives aiming at the development of new TB vaccines. TBVI will be established as a legal entity stemming from TBVAC, the FP6 EC supported project on TB vaccines, that has proven remarkably successful. TBVI will aim to facilitate the completion of vaccine development by their respective developers, and will not claim the ownership of any new products nor IP rights. Specific objectives of TBVI will be: a-To establish a working group to ensure coordination of activities related to TB vaccine development. It will comprise leaders of AERAS, BMGF, Stop TB (vaccines), TBVI and related EC projects. Regular meetings will be organized to define approaches regarding pre-clinical and clinical development. b- To advocate efforts towards the completion of TB vaccine development, including the mobilization of additional resources. c- To sustain and expand project management activities in the area of TB vaccine development . This will include advisory activities conducted through vaccine-specific product development teams (PDT) and management of specific European projects. The executive operational office will be based in ID-Lelystad (NL). A steering board comprising European scientists, with expertise in vaccine development, will meet on a monthly basis to decide on proposed and ongoing activities, development strategies and selection of new projects. A board of stakeholders/interested parties will review the overall activities and budget, and facilitate the mobilization of resources for TB vaccine development.'
Introduzione (Teaser)
The development of vaccines for tuberculosis is a pressing issue as international migration spreads and disease boundaries fall away.
Descrizione progetto (Article)
The 'Establishment, strategy and initial activities of the tuberculosis vaccine initiative: coordination of European efforts with global research initiatives' (ESI-TBVI) project worked to establish a Tuberculosis Vaccine Initiative (TBVI) as a private public partnership. The goal was to facilitate a productive link between EC-supported projects and worldwide initiatives working to develop new TB vaccines.
A TBVI working group was set up to enhance coordination of activities in the area of TB vaccine development. Regular meetings were held to define preclinical and clinical approaches, assist efforts to complete vaccine development, and sustain and expand relevant project management activities.
The TBVI was established in 2008 as a not-for-profit private foundation. Over 40 TBVI partners belong to 2 programmes for vaccine development: 1 for biomarkers and 1 for support in infrastructure activities and clinical trials development.
Both programmes are managed by a TBVI steering committee, which receives feedback from the product and clinical development teams (guiding the advancement of each product. A board of trustees advises the steering committee on strategic issues and approves the overall TBVI budget, while the governance board verifies process and financial resources of allocated project funds.
Supporting the steering committee, the board of trustees and governance board in their tasks, the operational office prepares project proposals, offers project management expertise and assists in mobilising resources. Activities to mobilise resources resulted in a USD-3-million grant from the Bill & Melinda Gates foundation and approval of the Seventh Framework Programme NEWTBVAC collaborative project proposal.
Meetings were held with various government officials in Belgium, Germany, Spain, France, Hungary, the Netherlands, Finland, Sweden and the UK. In Brussels a public debate was held in the European parliament on 24 March 2010, on the occasion of World Tuberculosis Day.
Annual reports of 2008 and 2009 and the TBVI website provide further information. These wide-ranging activities have created TB awareness and boosted efforts made by TBVI to boost TB vaccine development.